SODIUM HYALURONATE EYE DROPS IN THE TREATMENT OF DRY EYE DISEASE: AN OPEN LABEL, UNCONTROLLED, MULTI-CENTRE TRIAL

Authors

  • Alyscia Cheema
  • Tariq Aziz
  • Sajid Ali Mirza
  • Ahson Siddiqi
  • Neeta Maheshwary
  • Muhammad Athar Khan

Abstract

Background: Dry eye disease (DED) is one of the most frequently encountered ocular morbidities.The objective of this study was to assess the performance of sodium hyaluronate eye drop for eightweeks in patients with DED. Patients and Methods: This was a multi-centre, open-label,uncontrolled clinical trial carried out at different centres of Pakistan, from August 2009 to November2010. A total of 250 diagnosed patients of Dry Eye who met the inclusion criteria were included inthe study. After informed written consent, all patients having at least 2 of the Dry Eye symptoms,and at least 1 of the tests (Tear Film Break-up time (TBUT) ≤10 second, Schirmer’s test ≤6 mm/5min, and positive corneal staining) were enrolled. Tolerability/safety assessments consisted ofmonitoring and recording of adverse events and physical examinations at baseline, 4th week and 8thweek. Results: Out of 250 allocated patients 13 dropped out. The mean age of the patients was47.6±13.8 year and out of 237 patients 86 (36.3%) were men and 151 (63.7%) were women. At theinitial visit the foreign body sensation was 80%, itching 68%, burning 58%, watering 38%,photophobia 38%, and feeling of dryness was 16%. At the 3rd visit the foreign body sensationdecreased to 32%, itching to 32%, burning to 20%, watering to 12%, photophobia to 18%, andfeeling of dryness to 14%. Conclusion: Sodium hyaluronate has a beneficial effect on theconjunctival epithelium in a well-defined and homogeneous population of patients with dry eye andcan be considered useful for the treatment of dry eye.Keywords: Fluoresce in eye stain, Tear Break up Time, Schirmer’s test, Dry Eye Disease

References

O’Brien PD, Collum LM. Dry Eye: Diagnosis and current

treatment strategies. Curr Allergy Asthma Rep 2004;4:314–9.

International Dry Eye Workshop (DEWS). The definition and

classification of dry eye disease: report of the Definition and

Classification Subcommittee of the International Dry Eye

Workshop. Ocul Surface 2007;5:75–92.

Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact

of dry eye syndrome on vision-related quality of life. Am J

Ophthalmol 2007;143:409–15.

Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of

dry eye disease. Am J Manag Care 2008;14:S102–S106.

Moss SE, Klein R, Klein BE. Prevalence of and risk factors for

dry eye syndrome. Arch Ophthalmol 2000;118:1264–8.

Schaumberg DA, Sullivan DA, Buring JE, Dana MR.

Prevalence of dry eye syndrome among US women. Am J

Ophthalmol 2003;136:318–26.

Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry

eye syndrome. Adv Exp Biol Med 2002;506:989–98.

Malik TA, Naqvi SAH, Shahid M. Dry eye syndrome; frequency

in adult patients attending the eye clinic in Military Hospital

Rawalpindi. Professional Med J 2009;16(1):145–58.

Nelson JD, Farris LR. Sodium hyaluronate and polyvinyl-alcohol

artificial tears preparations. A comparison in patients with keratoconjunctivitis sicca. Arch. Ophthalmol. 1988; 106:484–7.

Papa V, Aragona P, Russo S, Di Bella A, Russo P, Milazzo

G. Comparison of hypotonic and isotonic solutions containing

sodium hyaluronate on the symptomatic treatment of dry eye

patients. Ophthalmologica 2001;215:124–7.

Fukuda K, Miyamoto Y, Miyara Y. Hyaluronic acid in tear fluid

and its synthesis by corneal epithelial cells. Asia Pacific J

Ophthalmol 1998;40:62–5.

Troiano P, Monaco G. Effect of hypotonic 0.4% hyaluronic acid

drops in dry eye patients: a cross-over study. Cornea

;27(10):1126–30. doi: 10.1097/ICO.0b013e318180e55c.

Inoue M, Katakami C. The effect of hyaluronic acid on corneal

epithelial cell proliferation. Invest Ophthalmol Vis Sci

;34(7):2313–5.

Nishida T, Nakamura M, Mishima H, Otori T. Hyaluronan

stimulates corneal epithelial migration. Exp Eye Res

;53:753–8.

Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy

and safety of 0.18% sodium hyaluronate in patients with moderate

dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp

Ophthalmol 2005;243(6):531–8.

Sand BB, Marner K, Norn MS. Sodium hyaluronate in the

treatment of keratoconjunctivitis sicca. A double masked clinical

trial. Acta Ophthalmol (Copenh) 1989;67(2):181–3.

Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK,

Pflugfelder SC. The pathology of dry eye: the interaction

between the ocular surface and lachrymals gland. Cornea

;17:584–9.

Snibson GR, Greaves JL, Soper ND, Tiffany JM, Wilson CG,

Bron AJ. Ocular surface residence times of artificial tears

solutions. Cornea 1992;11:288–93.

Takamura E, Tsubota K, Watanabe H, Ohashi Y A

randomised, double-masked comparison study of diquafosol

versus sodium hyaluronate ophthalmic solutions in dry eye

patients. Br J Ophthalmol 2012;96(10):1310–5. doi:

1136/bjophthalmol-2011-301448.

Downloads

Published

2012-12-01

Most read articles by the same author(s)